Contrasting of BioLineRx Ltd. (BLRX) and Moderna Inc. (NASDAQ:MRNA) – The Broch Herald

As Biotechnology businesses, BioLineRx Ltd. (NASDAQ:BLRX) and Moderna Inc. (NASDAQ:MRNA), are affected by compare. This especially applies to their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Demonstrates BioLineRx Ltd. and Moderna Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Institutional & Insider Ownership

Roughly 27.13% of BioLineRx Ltd. shares are held by institutional investors while 42.4% of Moderna Inc. are owned by institutional investors. Insiders held roughly 3.46% of BioLineRx Ltd.s shares. On the other hand, insiders held about 26.31% of Moderna Inc.s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year BioLineRx Ltd.s stock price has bigger decline than Moderna Inc.

Summary

Moderna Inc. beats BioLineRx Ltd. on 7 of the 10 factors.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companys other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome. The company has strategic collaborations with Novartis Pharma AG; Merck; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; Genentech Inc. to investigate the combination of BL-8040 and Genentechs Atezolizumab in various Phase Ib studies for multiple solid tumor indications and acute myeloid leukemia. BioLineRx Ltd. was founded in 2003 and is headquartered in Modiin, Israel.

Marina Biotech, Inc., a biopharmaceutical company, engages in the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. The company has three clinical development programs, such as IT-102 and IT-103, a celecoxib program drug candidates for the treatment of combined arthritis pain/hypertension and the treatment of pain requiring a high dose of celecoxib; CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication of familial adenomatous polyposis; and CEQ508 combined with IT-103 to treat colorectal cancer. Its preclinical pipeline includes oligotherapeutics for the treatment of bladder cancer, inflammatory bowel, and duchenne muscular dystrophy diseases. The company is based in City of Industry, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

View post:

Contrasting of BioLineRx Ltd. (BLRX) and Moderna Inc. (NASDAQ:MRNA) - The Broch Herald